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INTRODUCTION
Since 1959, the American Joint Committee on Cancer 
(AJCC) has published seven editions of the tumor-node-
metastasis (TNM) system for cancer staging. In 2017, the 
8th edition was announced, in which the revisions were 
based on the highest level of evidence from newly acquired 
clinical and pathological data (1). In a fundamental change, 
breast cancer is now considered as a group of diseases with 
different molecular characteristics that indicate different 
prognoses, patterns of recurrence, disseminations, and 
sensitivities to available therapies (2). Therefore, the 
Introduction of a New Staging System of Breast Cancer 
for Radiologists: An Emphasis on the Prognostic Stage
Jieun Koh, MD1, 2, Min Jung Kim, MD, PhD1
1Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul, Korea; 
2Department of Radiology, CHA Bundang Medical Center, CHA University, Seongnam, Korea 
In 2017, the American Joint Committee on Cancer announced the 8th edition of its cancer staging system. For breast 
cancer, the most significant change in the staging system is the incorporation of biomarkers into the anatomic staging to 
create prognostic stages. Different prognostic stages are assigned to tumors with the same anatomic stages according to 
the tumor grade, hormone receptor (estrogen receptor; progesterone receptor) status, and HER2 status. A Clinical Prognostic 
Stage is assigned to all patients regardless of the type of therapy used; in contrast, a Pathologic Prognosis Stage is assigned 
to patients in whom surgery is the initial treatment. In a few situations, low Oncotype DX recurrence scores can change the 
prognostic stage. The radiologists need to understand the importance of the biologic factors that can influence cancer staging.
Keywords: Breast neoplasm; TNM stage; Biomarker; AJCC; Prognostic stage
Received April 12, 2018; accepted after revision July 9, 2018.
This study was supported by the Basic Science Research Program 
of the National Research Foundation of Korea funded by the 
Ministry of Science, ICT & Future Planning, Republic of Korea (grant 
2017R1A2B4010407).
Corresponding author: Min Jung Kim, MD, PhD, Department of 
Radiology, Severance Hospital, Research Institute of Radiological 
Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, 
Seodaemun-gu, Seoul 03722, Korea. 
• Tel: (822) 2228-7400 • Fax: (822) 393-3035
• E-mail: mines@yuhs.ac
This is an Open Access article distributed under the terms of 
the Creative Commons Attribution Non-Commercial License 
(https://creativecommons.org/licenses/by-nc/4.0) which permits 
unrestricted non-commercial use, distribution, and reproduction in 
any medium, provided the original work is properly cited. 
committee incorporated biomarkers (histologic grade, 
hormone receptor, HER2 expression, and multigene panels) 
into the traditional anatomic TNM staging (1). Here, we 
introduce the major changes of the 8th edition of the 
AJCC staging system of breast cancer to radiologists, 
by presenting representative cases that will be staged 
differently under the new system. The changes in the 8th 
edition are briefly summarized in Table 1.
Brief Overview of the 7th Edition 
The 7th edition of the AJCC staging system was mainly 
based on anatomical staging, which used the extent of 
the primary tumor (T), status of the regional lymph nodes 
(N), and metastasis status (M). This has remained largely 
unchanged in the 8th edition. The T stage is based on the 
size and degree of loco-regional invasion by the primary 
tumor and is categorized from T1 to T4. The N stage is 
determined by the extent of nodal involvement including 
axillary, internal mammary, and ipsilateral supraclavicular 
lymph nodes. Distant metastases are evaluated to determine 
the M stage. The 7th edition used nine stages (0, IA, 
IB, IIA, IIB, IIIA, IIIB, IIIC, and IV) based on different 
combinations of T, N, and M status (Table 2).
Korean J Radiol 2019;20(1):69-82
eISSN 2005-8330
https://doi.org/10.3348/kjr.2018.0231
Pictorial Essay | Breast Imaging
70
Koh et al.
kjronline.orghttps://doi.org/10.3348/kjr.2018.0231
Changes in the Anatomic Stage 
The AJCC committee maintained the anatomic stages for 
countries in which the tests for biomarkers were unavailable 
and for uniformity in terminology with past studies and 
different researchers. In the 8th edition, the fundamental 
rules for anatomic staging have not been changed, but 
several previous ambiguous definitions have been clarified. 
Tumor
In the 8th edition, lobular carcinoma in situ has been 
removed from the in situ carcinoma (pTis) category and 
classified as a benign entity. Except for invasive carcinoma 
and ductal carcinoma in situ (DCIS) being included in the 
staging system, the criteria for the T categories remain the 
same as those in the 7th edition. DCIS and Paget disease of 
the nipple, not associated with parenchymal carcinoma, are 
classified as Tis (DCIS) and Tis (Paget disease). Categories 
T1–3 have been assigned to an invasive carcinoma without 
loco-regional invasion according to the size of the invasive 
component (Table 3). For staging, the maximum invasive 
tumor size is measured because it is a reasonable estimate 
of the tumor volume (Fig. 1) (3). The 8th edition clarifies 
that only the maximum dimension of the largest tumor is 
measured, without adding small microscopic satellite foci of 
the tumor. In that case, multiple cancers are documented 
using the modifier (m) (Fig. 2). On imaging, the 
measurement of the largest tumor should be combined with 
the size of microcalcifications or architectural distortions 
associated with the primary tumor, because they could 
influence the surgical extent. The T1 category is defined 
as a tumor of 20 mm or less and is divided into T1mi (≤ 
1 mm), T1a (> 1 mm but ≤ 5 mm), T1b (> 5 mm but ≤ 10 
mm), and T1c (> 10 mm but ≤ 20 mm); T2 category are 
tumors > 20 mm but ≤ 50 mm; T3 category are tumors 
> 50 mm (1). The T4 category is assigned when there is 
Table 1. Summary of Changes in 8th Edition
Changes in anatomic stages (T, N, M)
Clarification of previously 
ambiguous definitions (T)
Maximum dimension of largest tumor is measured not adding satellite foci
Multiple cancers are documented using (m) modifier
Satellite tumor nodules in skin should be separate from main mass to qualify T4b
Measurement of metastatic lymph 
node on pathology (N)
Pathologic staging of lymph node metastases uses only largest contiguous tumor deposit for pN
Definition of distant metastasis (M) pM0 is not valid category; cM0, cM1, and pM1 are used
Clarification of post neoadjuvant therapy staging
After neoadjuvant therapy, ycTNM and ypTNM classification are used
Response to neoadjuvant chemotherapy is evaluated as complete response, partial response, and no response
Adoption of prognostic staging (Clinical and Pathologic Prognostic Stages) 
Inclusion of biomarkers: tumor grade, hormone receptors, and HER2
Inclusion of multigene panels (Oncotype DX)
Clinical Prognostic Stage is assigned to all patients regardless of type of therapy they receive
Pathologic Prognostic Stage is assigned to patients who receive surgery as initial treatment (excluding patients who receive 
neoadjuvant chemotherapy)
M = metastasis, N = nodes, pN = pathologic N, T = tumor, TNM = tumor-node-metastasis
Table 2. 7th Edition of American Joint Committee on Cancer 
Staging System for Breast Cancer 
Stage Tumor Node Metastasis
0 Tis N0 M0
IA T1 N0 M0
IB T0 N1mi M0
T1 N1mi M0
IIA T0 N1 M0
T1 N1 M0
T2 N0 M0
IIB T2 N1 M0
T3 N0 M0
IIIA T0 N2 M0
T1 N2 M0
T2 N2 M0
T3 N1 M0
T3 N2 M0
IIIB T4 N0 M0
T4 N1 M0
T4 N2 M0
IIIC AnyT N3 M0
IV AnyT AnyN M1
Tis = in situ, mi = micrometasis
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either chest wall or skin invasion by the breast cancer cells. 
Extension into the chest wall is T4a category and it means 
invasion of the ribs, intercostal muscles, and serratus 
anterior muscle; however, invasion of only the pectoral 
muscles does not qualify as T4. Magnetic resonance imaging 
(MRI) provides a more accurate assessment of chest wall 
extension than mammography or ultrasound (4). Satellite 
tumor nodules in the skin are T4b, but the nodules must 
be separate from the primary tumor and macroscopically 
identified (Fig. 3). Ulceration or edema of less than one-
third of the skin of the breast, which does not qualify as 
inflammatory breast cancer (IBC), is regarded as T4b. On the 
MRI, direct skin invasion causes skin thickening, multiple 
nodules, ulceration, and a fungating mass (5). Invasion of 
the dermis alone does not qualify as T4; a T4c category is 
determined when conditions of both T4a and T4b are met 
(Fig. 4). IBC (T4d) is primarily a clinical diagnosis made 
when diffuse erythema and edema involving at least one-
third of the skin of the breast is observed (Fig. 5). It is 
highly aggressive with rapid evolution and is associated 
with poor prognosis (6, 7); therefore, a neglected, locally 
advanced breast cancer should not be classified as IBC. 
On mammography, IBC presents as diffuse skin thickening 
and trabecular distortion, whereas, on ultrasound, it 
presents a mass or parenchymal distortion and diffuse skin 
thickening. On MRI, the primary lesions present mostly as 
multiple small, confluent, enhancing nodules accompanied 
with diffuse skin thickening (8, 9). For the T staging of 
breast cancer on imaging, the longest diameter should be 
measured, multiple tumor nodules should be identified, 
and loco-regional invasion should be evaluated by careful 
examination of the nipple, skin, and underlying chest wall. 
Table 3. Definition of Primary T Categories
Stage Definition
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis (DCIS) Ductal carcinoma in situ
Tis (Paget’s)
Paget’s disease of nipple NOT associated with invasive carcinoma and/or carcinoma in situ (DCIS) in underlying breast 
parenchyma. Carcinomas in breast parenchyma associated with Paget disease are categorized based on size and 
characteristics of parenchymal disease, although presence of Paget disease should still be noted
T1 Tumor ≤ 20 mm in greatest dimension
T1mi Tumor ≤ 1 mm in greatest dimension
T1a Tumor > 1 mm but ≤ 5 mm in greatest dimension (round any measurement 1.0–1.9 mm to 2 mm)
T1b Tumor > 5 mm but ≤ 10 mm in greatest dimension  
T1c Tumor > 10 mm but ≤ 20 mm in greatest dimension  
T2 Tumor > 20 mm but ≤ 50 mm in greatest dimension  
T3 Tumor > 50 mm in greatest dimension
T4
Tumor of any size with direct extension to chest wall and/or to skin (ulceration or macroscopic nodules);  
invasion of dermis alone does not qualify as T4 
T4a Extension to chest wall, not including only pectoralis muscle adherence/invasion
T4b
Ulceration and/or ipsilateral macroscopic satellite nodules and/or edema (including peau d’orange) of skin,  
which do not meet criteria for inflammatory carcinoma
T4c Both T4a and T4b
T4d Inflammatory carcinoma
Fig. 1. Measurement of tumor size. Maximum tumor size 
measures 4.3 cm on ultrasound image (arrow). It also measures 4.3 cm 
pathologically. Therefore, both clinical and pathologic T category is 
T2. T = tumor 
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Lymph Nodes
Unlike T categories, nodal staging uses separate clinical 
N (cN) and pathologic N (pN) categories. For the clinical 
evaluation of the node status, the 8th edition does not 
contain any significant changes from the 7th edition 
(Table 4). Although the clinical stage can be determined 
without an imaging evaluation, imaging is valuable in 
assessing regional lymph node metastases. The method of 
confirmation of metastatic lymph nodes should be noted: 
cN, confirmed by clinical findings; cN(f), confirmed by fine-
needle aspiration or core biopsy; or cN(sn), confirmed by 
sentinel node biopsy. The regional lymph nodes occur in 
the ipsilateral axillary, ipsilateral internal mammary, and 
ipsilateral supraclavicular areas. The levels of axillary lymph 
nodes are defined using the pectoralis minor muscle as a 
landmark: level I lymph nodes are on the lateral border of 
the pectoralis minor muscle, level II nodes are between 
the medial and lateral borders of the pectoralis minor 
muscle, and level III nodes are on the medial border of 
pectoralis minor muscle. Imaging findings for metastatic 
axillary lymph nodes include loss of fatty hilum, eccentric 
cortical thickening, round shape, extranodal extension, 
and marked hypoechoic cortex on the ultrasound (10); 
round or irregular shape, increased density, or loss of fatty 
hilum on mammography (11); and loss of fatty hilum (12), 
round shape (13), and eccentric cortical thickening on 
MRI (13, 14). The cN1 indicates metastases to one or more 
movable, ipsilateral, levels I and II axillary lymph nodes. 
The cN2a indicates metastases to fixed, ipsilateral, levels I 
and II axillary lymph nodes; cN2b indicates metastases to 
ipsilateral internal mammary lymph nodes without evidence 
of axillary lymph node metastases. The cN3a indicates 
ipsilateral level III lymph nodes regardless of the status 
of levels I and II axillary lymph (Fig. 6); cN3b indicates 
Fig. 2. Determination of T categories. 
A. Maximum size of largest tumor is measured (solid line), but size of smaller tumors is not added (dotted line). B. Magnetic resonance maximum 
intensity projection image demonstrates multiple synchronous tumors in breast. Maximum invasive size of largest tumor is 2.4 cm (arrow), and 
size of smaller tumors (arrowheads) is not added. Therefore, cT2 (m) is designated for T stage.
A B
Fig. 3. T4b breast cancer. MRI shows primary breast cancer in left 
upper breast (arrowheads). Separate skin nodule is identified at left 
upper outer part, which qualifies as T4b (arrow). MRI = magnetic 
resonance imaging
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Fig. 4. T4c breast cancer. 
A. MRI shows left breast cancer with skin ulceration (arrow) and rib extension (arrowheads). B. Physical examination shows ulceration extending 
to less than one third of breast, which does not meet definition of IBC. IBC = inflammatory breast cancer
A B
A B
Fig. 5. Left IBC (T4d). 
A. MRI shows diffuse skin enhancement (arrowheads) and chest wall extension (arrow). B. Physical examination of left breast shows erythema 
and peau d’orange (orange peel skin) appearance of skin, which meets definition of IBC.
Table 4. Definition of Clinical Regional Lymph N Categories
Stage Definition
cNX Regional lymph nodes cannot be assessed (for example, previously removed)
cN0 No regional lymph node metastases
cN1 Metastases to movable ipsilateral level I, II axillary lymph node(s)
cN2
Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected 
ipsilateral internal mammary nodes in absence of clinically evident axillary lymph node metastases
cN2a Metastases in ipsilateral level I, II axillary lymph nodes fixed to one another (matted) or to other structures
cN2b
Metastases only in clinically detected ipsilateral internal mammary nodes and in absence of clinically evident level I, II 
axillary lymph node metastases
cN3
Metastases in ipsilateral infraclavicular (level III axillary) lymph node(s) with or without level I, II axillary lymph node 
involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II 
axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or 
internal mammary lymph node involvement
cN3a Metastases in ipsilateral infraclavicular lymph node(s)
cN3b Metastases in ipsilateral internal mammary lymph node(s) and axillary lymph node(s)
cN3c Metastases in ipsilateral supraclavicular lymph node(s)
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both ipsilateral internal mammary and axillary lymph 
node metastases (Fig. 6); and cN3c indicates ipsilateral 
supraclavicular lymph node metastases (Fig. 6). 
The 8th edition clearly indicates that pathologic staging 
of lymph node metastases uses only the largest contiguous 
tumor deposit for pN. Pathologic classification is defined 
by the regions of lymph nodes involved and the number of 
ipsilateral axillary lymph node metastases (Table 5). The 
American College of Surgeons Oncology Group Z0011 trial 
sparked debates about whether an imaging evaluation of 
axillary lymph nodes should be performed (15, 16). Since 
patients with T1 or T2 tumors, undergoing only a sentinel 
node biopsy, did not have an inferior survival rate compared 
to those who received a complete axillary node dissection, 
some researchers argued that an imaging evaluation of 
axillae for early stage breast cancer was unnecessary (16). 
However, the axillary evaluation retained its importance in 
other studies (17, 18). An evaluation of the axillary lymph 
nodes should cover both levels I and II. When lymph node 
metastases are suspected, the level III internal mammary 
chain, and supraclavicular area should also be evaluated.
Metastasis
Stage M1 is designated when distant metastases are 
found, including contralateral lymph node metastases (Table 
6). Metastases can be detected in various imaging studies. 
The 8th edition clarifies that pM0 is not a valid category; 
benign biopsy of a suspicious lesion does not guarantee the 
absence of metastatic lesions elsewhere, and therefore, only 
cM0, cM1, and pM1 grades are used. The most common sites 
of breast cancer metastases are bone, lung, brain, and liver 
(19). Category M1 indicates stage IV disease regardless of 
T or N status and shows the poorest prognosis. For patients 
with stage I–IIB, systemic evaluation including bone scan, 
abdominal computed tomography (CT), or chest CT is only 
recommended when there are clinical signs, symptoms, 
or laboratory abnormalities suggesting metastases. For 
patients with a locally advanced disease, screening systemic 
Fig. 6. cN3 category. 
A, B. cN3a: Ultrasound images from right breast cancer case show enlarged hypoechoic lymph nodes with loss of fatty hilum not only in right 
axilla (A) level II (arrows), but also on (B) level III (arrow). Note pectoralis minor muscle (arrowheads), which is landmark for grouping axillary 
lymph nodes. C, D. cN3b: (C) MRI of case of cancer in right breast shows enlarged lymph nodes in right axilla (arrow). (D) Enlarged right 
internal mammary lymph node is also noted (arrowhead). E, F. cN3c: (E) Ultrasound of left breast cancer case shows enlarged lymph node in left 
axilla (arrow). (F) Enlarged left supraclavicular lymph node is also noted (arrowhead). AX = axilla
A B C
D E F
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evaluation using positron emission tomography can be 
performed (Fig. 7) (20). 
Post-Neoadjuvant Therapy Staging
Neoadjuvant therapy is widely performed in locally 
advanced breast cancer, IBC, and even operable breast 
cancer (21). After neoadjuvant therapy, the y prefix is used. 
The ycT is determined by measuring the largest single focus 
of the residual tumor by examination or imaging (Fig. 8). 
When there is no residual disease, it is classified as ycT0. 
IBC (cT4d) retains the same classification stage even if 
complete resolution of the tumor is observed. The ycN is 
determined by clinical or radiographic findings of residual 
lymph nodes. Pre-treatment M1 disease is designated as 
M1 throughout treatment. When surgery is performed after 
neoadjuvant chemotherapy, the yp classification is applied. 
The response to neoadjuvant chemotherapy is evaluated as 
complete response (CR), partial response, or no response. 
CR is designated to the tumor when residual invasive cancer 
is not found in the breast tissue and lymph nodes, clinically 
or pathologically (Fig. 9). The presence of in situ cancer 
constitutes a pathologic CR. Partial response is defined 
as a decrease in the T or N category without any evidence 
of increase in either the T or N category. No change or an 
increase in the T or N category is defined as no response. 
Table 5. Definition of Pathologic Regional Lymph N Categories
Stage Definition
pNX Regional lymph nodes cannot be assessed (e.g., not removed for pathological study or previously removed)
pN0 No regional lymph node metastasis identified or ITCs only
pN0 (i+) ITCs only (malignant cell clusters no larger than 0.2 mm) in regional lymph node(s)
pN0 (mol+) Positive molecular findings by reverse transcriptase-polymerase chain reaction; no ITCs detected
pN1
Micrometastases; or metastases in 1–3 axillary lymph nodes; and/or clinically negative internal mammary lymph nodes 
with micrometastases or macrometastases by sentinel lymph node biopsy
pN1mi Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm)
pN1a Metastases in 1–3 axillary lymph nodes, at least one metastasis larger than 2.0 mm
pN1b Metastases in ipsilateral internal mammary sentinel lymph nodes, excluding ITCs
pN1c pN1a and pN1b combined
pN2
Metastases in 4–9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in absence  
of axillary lymph node metastases
pN2a Metastases in 4–9 axillary lymph nodes (at least one tumor deposit larger than 2.0 mm)
pN2b
Metastases in clinically detected internal mammary lymph nodes with or without microscopic confirmation;  
with pathologically negative axillary lymph nodes
pN3
Metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive 
ipsilateral internal mammary lymph nodes by imaging in presence of one or more positive level I and II axillary lymph 
nodes; or in more than 3 axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy 
in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes
pN3a
Metastases in 10 or more axillary lymph nodes (at least one tumor deposit larger than 2.0 mm); or metastases to 
infraclavicular (level III axillary lymph) nodes
pN3b pN1a or pN2a in presence of cN2b (positive internal mammary lymph nodes by imaging); or pN2a in presence of pN1b
pN3c Metastases in ipsilateral supraclavicular lymph nodes
ITCs = isolated tumor cells
Table 6. Definition of Distant M Categories
Stage Definition
M0 No clinical or radiographic evidence of distant metastases
cM0 (i+)
No clinical or radiographic evidence of distant metastases, but deposits of molecularly or microscopically detected tumor cells 
in circulating blood, bone marrow, or other non-regional nodal tissue that are no larger than 0.2 mm in patient without 
symptoms or signs of metastases
cM1 Distant metastases detected by clinical and radiographic means
pM1 Any histologically proven metastases in distant organs; or if in non-regional nodes, metastases greater than 0.2 mm
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Adoption of the Prognostic Stage
For the 8th edition, the AJCC committee created the 
prognostic staging protocol. This integrates biomarkers into 
the TNM staging system, making use of the results from 
large cohort studies, which shows that not only pathologic 
stage, but also different biomarkers could affect survival 
(1, 22). The biomarkers indicate tumor grade, hormone 
receptor status, and HER2. Multigene panel status is also 
incorporated into the staging system in limited sub-groups. 
The 8th edition defines clinical and pathologic prognostic 
stages that combine anatomic staging with tumor grade, 
hormone receptor status, and HER2 status (Figs. 10, 11).
Tumor Grade
Tumor grade is an important prognostic factor 
independent of the tumor size and number of positive lymph 
nodes (23). Tumor grade reflects tumor differentiation with 
worse prognosis observed in tumors with a high histologic 
grade or poor differentiation, than those with a low grade 
or well-differentiated (Fig. 12) (24). A modified Scarff-
Bloom-Richardson system measuring tubules (glands), 
nuclear pleomorphism, and mitotic counts is used to 
evaluate the tumor grade (24, 25). 
Hormone Receptor and HER2 Expression
Evaluating the expression of estrogen receptors (ERs) and 
progesterone receptors (PRs) in breast cancer is important, 
because selective ER modulators slow the progression of 
ER-positive and PR-positive tumors (26, 27). Furthermore, 
breast cancer is related to several oncogenes including 
HER2. The presence of HER2 is associated with a poor 
prognosis in untreated patients (28-30). However, HER2 
targeting agents (trastuzumab) improve the prognosis for 
patients with HER2 positive tumors (31, 32). A high Ki-67 
level reflects rapidly dividing tumor cells, although there 
is no universal cut-off for measuring Ki-67 levels (33, 34). 
According to the ER/PR and HER2 status and with additional 
information about Ki-67, the 8th edition identifies four 
subtypes: luminal A (hormone receptor–positive, HER2-
negative, low Ki-67), luminal B (hormone receptor–
positive, HER2-negative, high Ki-67), HER2 (HER2-positive 
regardless of the hormone receptor status), and basal (both 
hormone receptor and HER2 negative) (35, 36). The luminal 
Fig. 7. Right breast cancer with lung metastasis (M1). On 
positron emission tomography-computed tomography, 10-cm cancerous 
mass is seen in right breast and multiple FDG uptakes are seen in right 
axillary lymph nodes (arrow); there are lung nodules with FDG uptake, 
suggesting lung metastasis (arrowhead).  FDG = fludeoxyglucose, M = 
metastasis 
Fig. 8. Size measurement after neoadjuvant chemotherapy. 
A. Initial MRI shows 4.3-cm irregular breast cancer in left breast (T2) (arrow). B. After neoadjuvant chemotherapy, cancer reduced to multiple 
small masses (arrowheads); largest one measures 10 mm (arrow). Therefore, post treatment T category is ycT1b (m). 
A B
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A type has the best prognosis, with excellent response to 
endocrine therapies. The luminal B type is less responsive 
to endocrine therapies and has worse prognosis than the 
luminal A type. The HER2 type responds to HER2 targeting 
agents and proper treatment improves the prognosis. The 
basal type, also known as a triple-negative tumor, has the 
worst prognosis (Fig. 13). 
Multigene Panel Status
Multigene panel tests measure the expression levels 
of a large number of genes in breast cancer tissue, and 
several panels are available for the same. Among them, 
Oncotype DX has the best available evidence, and thus, 
it is the one incorporated into the 8th edition (37-41). 
Based on this evidence, patients with hormone receptor–
positive, HER2-negative, and lymph node–negative tumors 
with a recurrence score less than 11 on the Oncotype DX, 
are placed into stage I (T1a-T1bN0M0) regardless of T 
size. Other multigene panels, including Mammaprint (42), 
EndoPredict (43, 44), PAM50 (45, 46), and the Breast 
Cancer Index (47, 48) have shown results similar to those 
of Oncotype Dx, but at present they are not included in the 
TNM staging system.
Fig. 9. Patient with cancer in right breast with MRI before (A, B) and after neoadjuvant chemotherapy (C, D). A. Initial MRI 
shows 2.2-cm right breast cancer (arrow). B. Ipsilateral matted axillary lymph node enlargement is noted (arrows). Initial stage is T2N2aM0. C. 
After neoadjuvant chemotherapy, there is no residual mass. D. Axillary lymph nodes have disappeared, which suggests clinical CR (ycT0N0M0). 
Histopathologic evaluation shows absence of invasive carcinoma in breast and lymph nodes, indicating pathologic CR (ypT0N0M0). CR = complete 
response 
A B
C D
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Prognostic Stage Groups
Two large cohorts, the MD Anderson Cancer Center study 
(22) and the National Cancer Data Base (NCDB) study 
(David JW, unpublished data), were analyzed to incorporate 
biomarkers into prognostic staging (1). The first study 
identified risk profiles using not only pathologic stages, 
but also high tumor grade, ER-negative status, and HER2-
negative status (22, 49). The second unpublished study 
used the NCDB to reveal that patients with triple-negative 
tumors, regardless of grade, should be categorized at 
least one stage higher than other sub-types (David JW, 
unpublished data). Grade-3 tumors, HER2-negative, and 
ER-negative or PR-negative tumors should also have a 
higher stage (Fig. 14). Patients whose tumors expressed 
both ER and PR, with or without HER2 over-expression, 
had better survival (Fig. 15). Based on that study, the 
8th edition defines Clinical and Pathologic Prognostic 
Stages that combine anatomic staging with tumor grade, 
Fig. 10. Clinical Prognostic Stage is assigned to all patients regardless of type of therapy given. ER- = estrogen receptor-negative, 
ER+ = ER-positive, G = grade, HER2- = HER2 negative, HER2+ = HER2-positive, mi = micrometastasis, PR- = progesterone receptor-negative, PR+ = 
PR-positive, Tis = in situ
Fig. 11. Pathologic Prognostic Stage is assigned to patients who received surgery as initial treatment. Additionally, pT1, pT2, pN0, 
M0, ER+, and HER2- cancers are assigned as Pathologic Prognostic Stage group IA when Oncotype DX recurrence score is less than 11.
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hormone receptor (ER/PR) status, and HER2 status. 
A Clinical Prognostic Stage is assigned to all patients 
regardless of the type of therapy they received (Fig. 10). 
A Pathologic Prognostic Stage is assigned to patients 
who receive surgery as the initial treatment, excluding 
patients who receive neoadjuvant chemotherapy (Fig. 11). 
Using the NCDB data, three-year overall survival rate was 
calculated with the inclusion of grade, hormone receptor, 
and HER2 status. These results were compared with the 
7th edition, and downstaging or upstaging was performed 
for the 8th edition. Additionally, pT1–T2, pN0, M0, ER-
positive, and HER2-negative cancers were assigned as 
Pathologic Prognostic Stage group IA, when the Oncotype 
Fig. 12. Right breast cancer with low histologic grade. 
A. MRI demonstrates breast cancer measuring 2.3 cm in upper breast (arrow). B. Ultrasound shows enlarged, right axillary lymph node with 
eccentric cortical thickening (arrow). After partial mastectomy, cancer measures 2.5 cm with two level-I lymph node metastases. Cancer is ER+/
PR+ and HER2-. Histologic grade is 1, and anatomic stage is IIB (T2N1M0). However, due to low histologic grade and biomarker status, Clinical 
Prognostic Stage is IIA and Pathologic Prognostic Stage is IA.
A B
Fig. 13. cT1N0M0 cancer. MRI shows that cancer measures 1.3 cm 
(arrow). There is no suspicious lymph node enlargement. Pathology 
shows 0.9-cm grade-2 carcinoma, but no hormone receptor or HER2 
overexpression is noted. Therefore, anatomic stage is IA (T1N0M0), but 
it is triple negative cancer; thus, Clinical and Pathologic Prognostic 
Stages are higher, IB.
Fig. 14. cT2N0M0 cancer. MRI shows 3.7-cm enhancing cancer 
(arrow). No axillary metastasis is found. Anatomic stage is IIA. Tumor 
grade is 3, and hormone receptor and HER2 expressions are negative. 
This tumor has high histologic grade and is triple-negative; therefore, 
Clinical Prognostic Stage is higher, IIB.
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Dx recurrence score was less than 11 (Fig. 16). 
CONCLUSION
In the 8th AJCC staging system of breast cancer, 
anatomic staging is maintained and the traditional role 
of radiology remains important. Anatomic staging is still 
the main system when immunohistochemical examinations 
are unavailable. However, radiologists should understand 
the importance of biomarkers in breast cancer staging. 
Different prognostic stages are assigned to tumors with the 
same anatomic stage depending on the histologic grade, 
hormone receptor status, HER2 status, and multigene 
panels. Different prognostic stages will call for different 
therapies for breast cancers with the same anatomic stage; 
therefore, radiologists’ role in evaluating tumor response 
after appropriate therapies is also important. 
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